The use of molecular breast imaging to assess response in women undergoing neoadjuvant therapy for breast cancer: A pilot study

Clinical Nuclear Medicine

Volumn 37, Issue 4, 2012, Pages 344-350

  Wahner Roedler, Dietlind L ^a   Boughey, Judy C ^a   Hruska, Carrie B ^a   Chen, Beiyun ^a   Rhodes, Deborah J ^a   Tortorelli, Cindy L ^a   Maxwell, Robert W ^a   Cha, Stephen S ^a   Oconnor, Michael K ^a  

^a MAYO CLINIC   (United States)

Author keywords

molecular breast imaging; neoadjuvant chemotherapy; neoadjuvant therapy

Indexed keywords

ANASTROZOLE; CADMIUM; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PACLITAXEL; TRASTUZUMAB; ZINC;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CORRELATION COEFFICIENT; DRUG DOSE REGIMEN; DRUG UPTAKE; ECHOGRAPHY; FEMALE; HUMAN; MAMMOGRAPHY; MOLECULAR BREAST IMAGING; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; PILOT STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; SCINTILLATION CAMERA; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PILOT PROJECTS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84863254193     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31824437b3     Document Type: Article

References (27)

1. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001:96-102.
2. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224-4237.
3. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414-4422. (Pubitemid 350013847)
4. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-785. Erratum in: J Clin Oncol. 2008;26: 2793. (Pubitemid 351264391)
5. Smith IE, Lipton L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol. 2001;2:561-570. (Pubitemid 33586869)
6. Shenkier T, Weir L, Levine M, et al. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ. 2004;170: 983-994. (Pubitemid 38392196)
7. Chow LW, Yiu CC, Yip AY, et al. The future perspectives of breast cancer therapy. Biomed Pharmacother. 2006;60:259-262. (Pubitemid 44223941)
8. Herrada J, Iyer RB, Atkinson EN, et al. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res. 1997;3:1565-1569. (Pubitemid 27431564)
9. Helvie MA, Joynt LK, Cody RL, et al. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology. 1996;198:327-332. (Pubitemid 26036831)
10. Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006;243:257-264. (Pubitemid 43185446)
11. Warren RM, Bobrow LG, Earl HM, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer. 2004;90:1349-1360. (Pubitemid 38586259)
12. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol. 2003;181:1275-1282. (Pubitemid 37296403)
13. Hruska CB, Phillips SW, Whaley DH, et al. Molecular breast imaging: use of a dual-head dedicated gamma camera to detect small breast tumors. Am J Roentgenol. 2008;191:1805-1815.
14. OConnor M, Rhodes D, Hruska C. Molecular breast imaging. Expert Rev Anticancer Ther. 2009;9:1073-1080.
15. Schott AF, Roubidoux MA, Helvie MA, et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;92:231-238. (Pubitemid 41282819)
16. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004;14:1371-1379. (Pubitemid 39162217)
17. Trecate G, Ceglia E, Stabile F, et al. Locally advanced breast cancer treated with primary chemotherapy: comparison between magnetic resonance imaging and pathologic evaluation of residual disease. Tumori. 1999;85:220-228. (Pubitemid 29482205)
18. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007(suppl 1):S215-S229.
19. Mankoff DA, Dunnwald LK, Gralow JR, et al. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [Technetium 99m]-sestamibi scintimammography. Cancer. 1999;85: 2410-2423. (Pubitemid 29244850)
20. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-1695. (Pubitemid 30220547)
21. Tan PC, Pickles MD, Lowry M, et al. Lesion T(2) relaxation times and volumes predict the response of malignant breast lesions to neoadjuvant chemotherapy. Magn Reson Imaging. 2008;26:26-34. (Pubitemid 350299718)
22. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
23. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
24. Symmans WF, Volm MD, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res. 2000;6:4610-4617. (Pubitemid 32110395)
25. van Leeuwen FW, Buckle T, Batteau L, et al. Potential value of color-coded dynamic breast-specific gamma-imaging; comparing (99m)Tc-(V)-DMSA, (99m)Tc-MIBI, and (99m)Tc-HDP in a mouse mammary tumor model. Appl Radiat Isot. 2010;68:2117-2124.
26. Scopinaro F, Varvarigou A, Ussof W, et al. Breast cancer takes up 99mTc bombesin: a preliminary report. Tumori. 2002;88:S25-S28. (Pubitemid 34875469)
27. Scopinaro F, De Vincentis G, Varvarigou AD. Use of radiolabeled bombesin in humans. J Clin Oncol. 2005;23:3170-3171.